Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Brief Summary: The ROSORC trial is a randomized study comparing the efficacy of a new association (sorafenib and IL-2) versus the standard therapy (sorafenib) in patients affected by different histotypes of metastatic RCC. This study is a first line therapy for the advanced disease. The primary objective is the progression free survival (PFS) in the 2 arms of therapy and the secondary objective is the overall survival (OS) and the response rate (RR) and the safety profile of the combination compared to sorafenib alone.


Options:
A: Arm Label: Sorafenib-sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib-sunitinib | Arm Label: Sunitinib-sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib-sorafenib | Intervention Type: DRUG; Name: Sorafenib-sunitinib; Assigned to Arm(s): Sorafenib-sunitinib | Intervention Type: DRUG; Name: Sunitinib-sorafenib; Assigned to Arm(s): Sunitinib-sorafenib
B: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
C: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nexavar (Sorafenib), Drug: IL-2 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nexavar (Sorafenib) | Intervention Type: DRUG; Name: Nexavar (Sorafenib); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): 1

Answer: D